Another pooled analysis including 12 studies confirmed a tpCR rate of 30.9% for HER2-positive/HR-positive breast cancer in the presence of trastuzumab combined with chemotherapy, which was significantly lower than the 50.3% rate for HER2-positive/HR-negative patients [21]. Here, ERBB2 is linked to breast carcinoma.